Provided by Tiger Trade Technology Pte. Ltd.

Allogene Therapeutics Inc.

2.00
-0.0200-0.99%
Post-market: 2.000.0003+0.02%18:17 EDT
Volume:4.37M
Turnover:8.71M
Market Cap:690.00M
PE:-3.07
High:2.02
Open:2.01
Low:1.96
Close:2.02
52wk High:4.46
52wk Low:1.04
Shares:345.00M
Float Shares:262.00M
Volume Ratio:0.88
T/O Rate:1.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6510
EPS(LYR):-0.8652
ROE:-42.39%
ROA:-22.08%
PB:1.58
PE(LYR):-2.31

Loading ...

Allogene Shares Gain on Interim Data From Lymphoma-Treatment Trial

Dow Jones
·
Apr 13

Allogene Therapeutics Shares Rise 70% Premarket After Co's Blood Cancer Therapy Delays Cancer Relapse in Mid-Stage Study

THOMSON REUTERS
·
Apr 13

Allogene's blood cancer therapy delays cancer relapse in mid-stage study

Reuters
·
Apr 13

Allogene ALPHA3 interim analysis shows 58.3% MRD clearance with cema-cel in LBCL

Reuters
·
Apr 13

Allogene Therapeutics Inc: No Hospitalizations for Treatment-Related Adverse Events

THOMSON REUTERS
·
Apr 13

Allogene Therapeutics Reports Interim Futility Analysis From Pivotal Alpha3 Trial Showing 58.3% Mrd Clearance With Cemacabtagene Ansegedleucel (Cema-Cel) VS. 16.7% in Observation Arm in First-Line Consolidation Lbcl

THOMSON REUTERS
·
Apr 13

Allogene Therapeutics Inc - Enrollment Expected to Complete by Year-End 2027; Interim Efs Analysis in Mid-2027

THOMSON REUTERS
·
Apr 13

NASDAQ TRADE HALT HALT NEWS PENDING AT 07:25 AM

Reuters
·
Apr 13

Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Takeda Pharmaceutical Company (TAK)

TIPRANKS
·
Mar 31

Allogene Therapeutics Faces Trial Setback as ALLO-647 Halt Raises Lymphodepletion and Regulatory Timeline Risks

TIPRANKS
·
Mar 14

Allogene Therapeutics (ALLO) Gets a Buy from Piper Sandler

TIPRANKS
·
Mar 13

REFILE-Allogene Therapeutics Q4 net loss narrows

Reuters
·
Mar 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 11

Allogene Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
Mar 11

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 09